Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue: +1.33%
EPS: +418.2%
Free cash flow: −6.83%
Total debt: −42.2%

Quarter to June 2026, against a year earlier

72.75 0.09 +0.12%

Follow TECH

Alert me

Market cap: $11.4B
P/E: 62.2×
Fwd P/E: 54.2×
Dividend yield: 0.44%
F-score: 9/9
Altman Z: 15.50
Beneish M: −2.52
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Techne Corp (TECH) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Bio-Techne Corp (TECH) trades at a P/S ratio of 9.3×. Over the past ten years it has ranged from 5.6× (May 2026) to 22.4× (September 2021); the current reading is higher than 49% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TECH/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Bio-Techne Corp P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TECH/metrics/ps-ratio">Bio-Techne Corp (TECH) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2026	9.1×	36.47%
FY2025	6.6×	(31.80%)
FY2024	9.7×	(13.68%)
FY2023	11.3×	(8.20%)
FY2022	12.3×	(34.38%)
FY2021	18.7×	37.22%
FY2020	13.7×	23.32%
FY2019	11.1×	28.17%
FY2018	8.6×	10.93%
FY2017	7.8×	(7.33%)

Period	P/S ratio	Change
Jun 2026	9.1×	34.41%
Mar 2026	6.7×	(10.51%)
Dec 2025	7.5×	6.07%
Sep 2025	7.1×	6.97%
42 more quarters	Free account

Against its own ten years

Low 5.6× High 22.4×

Ten-year median 9.5×

Current reading's percentile 44

Company	P/S ratio
PCVX Vaxcyte, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	3.0×
CAI Caris Life Sciences,�Inc. compare	7.1×
TECH Bio-Techne Corp	9.3×
TGTX TG Therapeutics, Inc. compare	10.3×
TWST Twist Bioscience Corporation compare	17.6×
IBRX ImmunityBio, Inc. compare	51.0×
KYMR Kymera Therapeutics, Inc. compare	120×
SMMT Summit Therapeutics PLC compare	15,884×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Bio-Techne Corp (TECH) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on TECH

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on TECH

Stockrow Weekly